Investigational drug · Phase 3
CTO0308
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myopia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CTO0308"
First trial start
2025
Aug 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTO0308", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myopia
Largest trials
Live from ClinicalTrials.gov: studies naming "CTO0308" as an intervention, largest first.
- Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With MyopiaPivotal-lookingActive, not recruiting
Taejoon Pharmaceutical Co., Ltd.Industry
NCT07790640 · 351 participants · Start Aug 11, 2025 · Primary completion Apr 1, 2027
Drug: CTO0308; Vehicle (Placebo solution) · For: Myopia
Sites: Incheon, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myopia
- atropine sulfate eye dropsPhase 33 trials
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Myopia, Myopia Progression
- Lower sulfate eye dropsLower sulfatePhase 32 trials
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Myopia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.